# Novo-Nordisk (NVO)

Novo Nordisk's stock sees a post-market uptick following FDA actions against compounded GLP-1 drugs and the company's lawsuit against Hims & Hers, amidst ongoing discussions about Wegovy's performance and market competition.

### About Novo-Nordisk
Novo Nordisk is a pharmaceutical company specializing in diabetes and obesity treatments.  
Novo-Nordisk uses the ticker $NVO for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Novo-Nordisk (NVO) Galaxy Score™ is up 45.95% from the previous week.
- Novo-Nordisk (NVO) mentions is up 142.18% from the previous year.

### Price: $49.60
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/close.tsv)  
The stock price experienced a significant drop due to weak guidance and competition concerns. However, recent FDA actions against compounded GLP-1 drugs and Novo Nordisk's lawsuit against Hims & Hers have provided some support, leading to a slight post-market uptick.  

24-Hour: 1.31%
7-Day: 0.71%
30-Day: -20.47%

1-Year High: $91 on 2025-02-25  
1-Year Low: $43.30 on 2026-02-05  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/alt_rank.tsv)  
Novo-Nordisk (NVO) is currently AltRank #192 based on combined combined social and market metrics
Daily Average: [---]  
[--] Week: [---] +317  
[--] Month: [---] +91  
[--] Months: [---] +201  
[--] Year: [---] +218  
1-Year High: [-----] on 2025-07-05  
1-Year Low: [--] on 2025-03-30  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +17  
[--] Month: [--] +2  
[--] Months: [--] +1  
[--] Year: [--] +18  
1-Year High: [--] on 2025-06-10  
1-Year Low: [--] on 2025-06-25  
  
  
### Engagements: [-------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/interactions.tsv)  
Current Value: [-------]  
Daily Average: [-------]  
[--] Week: [---------] -45%  
[--] Month: [----------] +8.90%  
[--] Months: [-----------] +27%  
[--] Year: [-----------] +292%  
1-Year High: [----------] on 2025-08-26  
1-Year Low: [------] on 2025-02-28  

Engagements by network (24h):
TikTok: [------]
Reddit: [-----]
YouTube: [-----]
Instagram: [--]
X: [-------]

  
  
### Mentions: [-----] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/posts_active.tsv)  
Current Value: [-----]  
Daily Average: [-----]  
[--] Week: [-----] +23%  
[--] Month: [------] +29%  
[--] Months: [------] +67%  
[--] Year: [-------] +142%  
1-Year High: [-----] on 2025-11-07  
1-Year Low: [---] on 2025-03-01  

Mentions by network (24h):
TikTok: [---]
Reddit: [--]
YouTube: [--]
Instagram: [--]
X: [-----]

  
  
### Creators: [-----] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/contributors_active.tsv)  
[-----] unique social accounts have posts mentioning Novo-Nordisk (NVO) in the last [--] hours which is up 1.10% from [-----] in the previous [--] hours
Daily Average: [---]  
[--] Week: [-----] +9.80%  
[--] Month: [-----] +16%  
[--] Months: [------] +63%  
[--] Year: [------] +146%  
1-Year High: [-----] on 2025-11-07  
1-Year Low: [---] on 2025-03-01  

The most influential creators that mention Novo-Nordisk in the last [--] hours

| Creator                                            | Rank | Followers | Posts | Engagements |
| -------                                            | ---- | --------- | ----- | ----------- |
| [@TheLongInvest](/creator/twitter/TheLongInvest)   | [--]    | [-------]   | [--]    | [------]      |
| [@himshouse](/creator/twitter/himshouse)           | [--]    | [------]    | [--]    | [------]      |
| [@TacticzH](/creator/twitter/TacticzH)             | [--]    | [------]    | [--]    | [------]      |
| [@investseekers](/creator/twitter/investseekers)   | [--]    | [-----]     | [---]   | [------]      |
| [@A_May_MD](/creator/twitter/A_May_MD)             | [--]    | [------]    | [--]    | [------]      |
| [@novonordisk](/creator/tiktok/novonordisk)        | [--]    | [------]    | [--]    | [------]      |
| [@ShortSeller](/creator/twitter/ShortSeller)       | [--]    | [------]    | [--]     | [------]      |
| [@LEAPTRADER_](/creator/twitter/LEAPTRADER_)       | [--]    | [------]    | [--]     | [------]      |
| [@ResearchPulse1](/creator/twitter/ResearchPulse1) | [--]    | [-----]     | [--]    | [-----]       |
| [@dannycheng2022](/creator/twitter/dannycheng2022) | [--]   | [------]    | [--]     | [-----]       |

[View More](/list/creators/$nvo/100)
  
  
### Sentiment: 68%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/sentiment.tsv)  
Current Value: 68%  
Daily Average: 72%  
[--] Week: 66% +6%  
[--] Month: 63% -16%  
[--] Months: 63% -20%  
[--] Year: 63% -10%  
1-Year High: 88% on 2025-12-26  
1-Year Low: 27% on 2025-09-24  

Most Supportive Themes:
- Positive Clinical Trial Results and Wegovy's Cardiovascular Benefits: (35%) Posts highlighting positive results from clinical trials for Novo Nordisk's drugs, particularly Wegovy, and its cardiovascular benefits.
- Long-Term Growth Potential and Valuation: (25%) Posts discussing the long-term growth potential of Novo Nordisk, especially in the obesity and diabetes markets, and its current valuation.
- Expert Analysis and Recommendations: (15%) Posts from analysts and financial experts recommending Novo Nordisk as a buy or highlighting its strengths.
  
Most Critical Themes:
- Competition and Market Share Concerns: (20%) Posts expressing concerns about increasing competition from other pharmaceutical companies, particularly Eli Lilly, and its impact on Novo Nordisk's market share.
- Negative Guidance and Restructuring: (5%) Posts discussing the company's lowered sales and operating profit outlook, job cuts, and restructuring efforts.
  
  
  
### Social Dominance: 0.171%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/social_dominance.tsv)  
Current Value: 0.171%  
Daily Average: 0.216%  
[--] Week: 0.168% -0.219%  
[--] Month: 0.229% -0.066%  
[--] Months: 0.229% -0.13%  
[--] Year: 0.229% +0.022%  
1-Year High: 0.454% on 2025-11-06  
1-Year Low: 0.091% on 2025-12-07  
  
  
### Market Dominance: 0.25%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/market_dominance.tsv)  
Current Value: 0.25%  
Daily Average: 8%  
1-Year High: 14.40% on 2025-03-01  
1-Year Low: 0.25% on 2026-02-14  
  
  
### Market Cap: $220,423,745,530
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$nvo/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$nvo/time-series/market_cap.tsv)  
Current Value: $220,423,745,530  
Daily Average: $273,002,754,258  
[--] Week: $220,423,745,530 -0.67%  
[--] Month: $220,423,745,530 -13%  
[--] Months: $220,423,745,530 -7.70%  
[--] Year: $220,423,745,530 -36%  
1-Year High: $403,731,856,617 on 2025-02-25  
1-Year Low: $192,720,700,651 on 2026-02-05  

### Top Novo-Nordisk Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"GLP-1s may be Big Pharmas Napster moment. After the FDA referred $HIMS to the DOJ and $NVO sued over Ozempic/Wegovy copies the free-for-all era of mass compounding looks like its ending but the disruption isnt. Just like Napster iTunes Spotify the copycat phase may evolve into a new model: direct-to-consumer healthcare. Patients paying cash transparent pricing and platforms acting as gateways to branded drugs (e.g. Ro) could reshape distribution challenging PBMs and middlemen more than pharma itself. As Novo CEO Mike Doustdar put it: companies must decide if they want to be Napster or"  
[X Link](https://x.com/investseekers/status/2022706022737907925) [@investseekers](/creator/x/investseekers) 2026-02-14T16:14Z [----] followers, [----] engagements


"$NVO is aiming to capture around [--] million new patients when Medicare starts covering obesity treatments. $LLY $VKTX https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html https://www.cnbc.com/2026/02/11/novo-nordisk-ceo-medicare-coverage-opens-15-million-patient-opportunity.html"  
[X Link](https://x.com/BioStocks/status/2022695829866197019) [@BioStocks](/creator/x/BioStocks) 2026-02-14T15:34Z 71.3K followers, [----] engagements


"Why these names are seeing lower highs or crashes 🎯: Weekly Sell Signals: $NBIS $IREN $PATH $QS $ZETA $IONQ Monthly Sell Signals: $UNH $NVO $DUOL $HIMS $OSCR Swing Longs work best once the Weekly/Monthly Sell Signal completes"  
[X Link](https://x.com/datruthbomb/status/2022695345608958457) [@datruthbomb](/creator/x/datruthbomb) 2026-02-14T15:32Z [----] followers, [---] engagements


"$HIMS Shorts Up $1.3 Billion This Year. $NVO $LLY https://www.bloomberg.com/news/articles/2026-02-13/hims-hers-shorts-up-1-3-billion-this-year-on-legal-riskembedded-checkout=true https://www.bloomberg.com/news/articles/2026-02-13/hims-hers-shorts-up-1-3-billion-this-year-on-legal-riskembedded-checkout=true"  
[X Link](https://x.com/BioStocks/status/2022679426509705489) [@BioStocks](/creator/x/BioStocks) 2026-02-14T14:28Z 71.3K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing